

ORIGINAL ARTICLE

Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation

Christian E. Oberkofler¹  | Dimitri A. Raptis^{2,3} | Philip C. Müller¹ | Richard X. Sousa da Silva¹ | Kuno Lehmann¹ | Takahiro Ito⁴  | Timothy Owen² | Joerg-Matthias Pollok^{2,3} | Alessandro Parente⁵  | Andrea Schlegel⁵ | Peregrina Peralta⁶ | Erin Winter⁶ | Markus Selzner⁶ | Margot Fodor⁷ | Manuel Maglione⁷ | Manuel Jaklitsch⁸ | Hugo P. Marques⁸ | Mariana Chavez-Villa⁹ | Alan Contreras⁹ | Philipp Kron¹⁰ | Peter Lodge¹⁰ | Scott Alford¹¹ | Abbas Rana¹¹ | Paolo Magistri¹²  | Fabrizio Di Benedetto¹² | Bethany Johnson¹³ | Varvara Kirchner¹³ | Francis Bauldrick¹⁴ | Karim J. Halazun¹⁴ | Omid Ghamarnedjad¹⁵ | Arianeb Mehrabi¹⁵ | Samanta Teixeira Basto¹⁶ | Eduardo S. M. Fernandes¹⁶ | Jose Paladini¹⁷ | Martin de Santibañes¹⁷ | Sander Florman¹⁸ | Parissa Tabrizian¹⁸ | Philipp Dutkowski¹ | Pierre-Alain Clavien¹  | Ronald W. Busuttill⁴  | Fady M. Kaldas⁴ | Henrik Petrowsky¹ 

¹Swiss Hepato Pancreatico Biliary and Transplant Center Zurich, Department of Surgery and Transplantation, University Hospital Zurich, Zürich, Switzerland

²Department of Hepato Pancreatico Biliary Surgery and Liver Transplantation, Royal Free Hospital, London, UK

³Division of Surgery and Interventional Science, University College London, London, UK

⁴Dumont-University California Los Angeles Transplant Center, David Geffen School of Medicine at University California Los Angeles, Los Angeles, California, USA

⁵The Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK

⁶Multi-Organ Transplant Program, Department of Surgery, Toronto General Hospital, Toronto, Ontario, Canada

⁷Department of Visceral, Transplant, and Thoracic Surgery, Medical University Innsbruck, Innsbruck, Austria

⁸Hepato-Biliary-Pancreatic and Transplantation Center, Curry Cabral Hospital, Lisbon's Central Hospitals and University Center, Nova Medical School, Lisbon, Portugal

⁹Department of Surgery, Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Tlalpan, Mexico

¹⁰Leeds Teaching Hospital, NHS Trust, Hepato Pancreatico Biliary Surgery, Leeds, UK

¹¹Michael E. Debakey Department of Surgery, Division of Abdominal Transplantation and Division of Hepatobiliary Surgery, Baylor College of Medicine, Houston, Texas, USA

¹²Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy

¹³Department of Surgery, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA

¹⁴Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Weill Cornell Medicine, New York, New York, USA

¹⁵Department of General, Visceral and Transplantation Surgery, University Heidelberg, Heidelberg, Germany

Abbreviations: ACR, acute cellular rejection; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; CN1, calcineurin inhibitor; DBD, donation after brain death; DCD, donation after circulatory death; EAD, early allograft dysfunction; FFP, fresh frozen plasma; HAT, hepatic artery thrombosis; HCC, hepatocellular carcinoma; HJ, hepaticojejunostomy; HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; RAI, rejection activity index; RBC, red blood cell; RRT, renal replacement therapy; SRTR, Scientific Registry of Transplant Recipients; TACE, transarterial chemoembolization; TRIM, transfusion-related immunomodulation.

SEE EDITORIAL ON PAGE 1825

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Liver Transplantation* published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

¹⁶Department of General Surgery and Transplantation, Hospital Adventista Silvestre, and Department of Surgery, Faculty of Medicine, Universidade Federal Do Rio De Janeiro, Rio De Janeiro, Brazil

¹⁷Department of Surgery, Division of Hepato Pancreatico Biliary Surgery, Liver Transplant Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

¹⁸Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Correspondence

Henrik Petrowsky, Swiss Hepato Pancreatico Biliary and Transplant Center Zurich, Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Email: henrik.petrowsky@usz.ch

Abstract

This study investigated the effect of low-dose aspirin in primary adult liver transplantation (LT) on acute cellular rejection (ACR) as well as arterial patency rates. The use of low-dose aspirin after LT is practiced by many transplant centers to minimize the risk of hepatic artery thrombosis (HAT), although solid recommendations do not exist. However, aspirin also possesses potent anti-inflammatory properties and might mitigate inflammatory processes after LT, such as rejection. Therefore, we hypothesized that the use of aspirin after LT has a protective effect against ACR. This is an international, multicenter cohort study of primary adult deceased donor LT. The study included 17 high-volume LT centers and covered the 3-year period from 2013 to 2015 to allow a minimum 5-year follow-up. In this cohort of 2365 patients, prophylactic antiplatelet therapy with low-dose aspirin was administered in 1436 recipients (61%). The 1-year rejection-free survival rate was 89% in the aspirin group versus 82% in the no-aspirin group (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.63–0.94; $p = 0.01$). The 1-year primary arterial patency rates were 99% in the aspirin group and 96% in the no-aspirin group with an HR of 0.23 (95% CI, 0.13–0.40; $p < 0.001$). Low-dose aspirin was associated with a lower risk of ACR and HAT after LT, especially in the first vulnerable year after transplantation. Therefore, low-dose aspirin use after primary LT should be evaluated to protect the liver graft from ACR and to maintain arterial patency.

INTRODUCTION

Liver transplantation (LT) has become a standard therapy for patients with end-stage liver disease and fulminant liver failure. Postoperative morbidity still remains high,^[1] especially when accounting for vascular complications.^[2,3] Hepatic artery thrombosis (HAT) occurs in 4%–9% of adult LT^[4,5] and is one of the most serious vascular complications often resulting in liver necrosis, abscess formation, ischemic cholangiopathy, and graft loss. The sequel of these adverse events has a negative impact on graft and patient survival rates and remains a life-threatening complication with high mortality and retransplantation rates. In this context, the postoperative use of low-dose aspirin after LT is practiced by many transplant centers to reduce the incidence of HAT,^[6,7] although solid recommendations do not currently exist.

Apart from the antiaggregating effect, aspirin also possesses potent anti-inflammatory properties and is, therefore, widely used as a primary and secondary preventive medication against vascular disease.^[8] It inhibits pathways inherent to innate immunity, including

the production of thromboxan A₂,^[9] and downregulates proinflammatory signaling pathways, including nuclear factor kappa B.^[10,11] This indicates that aspirin might also mitigate inflammatory processes after LT such as rejection. Although data on the antirejection effect of low-dose aspirin do not exist in LT, there are divergent findings reported for other solid organ transplantations.^[12,13]

Therefore, we conducted this cohort study to evaluate whether antiplatelet therapy with aspirin has a protective effect on the occurrence and severity of acute cellular rejection (ACR) after LT. In addition to this analysis, we also assessed the effect of aspirin on arterial patency.

PATIENTS AND METHODS

Study design

This is an international, multicenter, retrospective cohort study of primary adult deceased donor LT. The study includes 17 high-volume LT centers from

Europe ($n = 8$), North America ($n = 6$), and Latin America ($n = 3$) and covers a 3-year period from 2013 to 2015 to allow a minimum 5-year follow-up (Figure S1). Each participating center required a prospective database from which data could be extracted. The project (aspirin4OLT) was implemented to investigate four specific aims regarding the effect of low-dose aspirin in patients after primary LT, including arterial patency, ACR, recurrence of hepatocellular carcinoma (HCC), and graft survival. Low-dose aspirin was defined as daily aspirin dose of 75–100 mg. We hypothesized that the use of aspirin after LT has a protective effect against ACR and lowers the incidence of HAT. All centers followed their standard of care for immunosuppression and decision making for allograft biopsies. The study has been approved by local ethic committees (2016-01889) and is registered at [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT04327427).

Data management

[Aspirin4OLT.org](https://aspirin4olt.org) is a clinical trial management system built on Drupal 7 that served as the backbone of our study by supporting administration, collaboration, communication, and information sharing needs among members from several participating centers worldwide. Fully anonymous patient data were stored in two separate secured sites with access given only to the relevant users. There were regular backups. Furthermore, the clinical trial management system was secured with a hypertext transfer protocol secure in combination with a secure sockets layer/transport layer security protocol and an encrypted structured query language database as previously described.^[14]

Inclusion and exclusion criteria

Inclusion criteria were adult (recipient age 18 years or older) deceased donor LTs. Donor organs from donation after brain death (DBD) or donation after circulatory death (DCD; Maastricht 3 criteria) donors were included. Further inclusion criteria included primary LT and whole organs as well as arterial reconstruction with end-to-end anastomosis and arterial back-table reconstruction. Other reconstruction techniques using an aorto- or iliac-hepatic conduit were excluded. We also excluded split-liver and living donor LT as well as retransplantations.

Posttransplant outcome measures

Primary outcome measures of the study were the occurrence of ACR and arterial patency after LT. Secondary

outcome measures included lengths of intensive care unit (ICU) and hospital stays and postoperative complications as well as graft and patient survival rates. Postoperative complications were ranked using the Clavien–Dindo classification.^[15] Lengths of ICU and hospital stays were measured from LT to discharge or death. Rejection-free survival was measured from transplantation to last follow-up or occurrence of ACR. Occlusion-free survival was measured from transplantation to last follow-up or arterial occlusion. Graft survival was measured from transplantation to last follow-up, retransplantation, or death. Patient survival was measured from transplantation to last follow-up or death.

Definition of ACR

ACRs, which were a primary outcome measure, were classified into clinically suspected without biopsy and histologically proven rejections. ACR was defined as a clinical entity in the absence of biopsy but in the setting of elevated liver function tests and treatment of suspected rejection in the respective transplant center.

Histologically proven ACRs were classified using the Banff rejection activity index (RAI).^[16] The RAI score uses the three categories of portal inflammation, bile duct inflammation, and venous endothelial inflammation, giving one to three points according to the inflammatory extend of each category. The various possible rejection grades were accordingly categorized as follows: 0–2, no rejection; 3, borderline; 4–5, mild; 6–7, moderate; and 8–9, severe ACR.^[17]

Definition of hepatic arterial patency

Primary patency, which was another primary outcome measure, was defined as time from transplantation or arterial anastomosis to occlusion or last patency follow-up. The definitions of primary patency of the hepatic artery are based on the reporting standards of the Society for Vascular Surgery and the American Association for Vascular Surgery.^[18]

Statistical analysis

The primary and secondary outcome measures were compared among different patient and operation characteristics with univariate analysis. Continuous data are reported as mean and standard deviation or median and interquartile range (IQR) where appropriate. Categorical data are reported as frequencies (n) and proportions (percentages). Continuous variables were compared with the Student t , Mann–Whitney

TABLE 1 Donor and recipient characteristics

	Total (n = 2365)	Aspirin (n = 1436)	No aspirin (n = 915)	p-value
<i>Donor characteristics</i>				
Demographics				
Age, years	49 (32–62)	48 (31–62)	50 (34–61)	0.55
DCD	241 (10)	149 (10)	92 (10)	0.83
<i>Recipient characteristics</i>				
Demographics				
Male sex	1587 (67)	966 (67)	614 (67)	0.96
Age, years	57 (49–62)	52 (49–63)	57 (49–62)	0.5
BMI, kg/m ²	27 (23–30)	27 (24–30)	26 (23–30)	<0.05
Liver disease				
MELD score	20 (13–29)	19 (13–29)	21 (14–29)	0.02
MELD score >30	576 (24)	348 (24)	227 (25)	0.77
Pretransplant life support ^a	375 (15)	197 (14)	175 (19)	<0.001
Ventilation	156 (6.6)	78 (5.4)	77 (8.5)	<0.05
RRT	326 (14)	172 (12)	151 (17)	<0.05
Vasopressor support	130 (5.5)	54 (3.8)	74 (8.1)	<0.001
HCC	858 (36)	514 (36)	337 (37)	0.63
Prior TACE	483 (29)	322 (33)	157 (23)	<0.001
Prior radiation	81 (5.1)	47 (5.0)	33 (5.0)	1
Cardiovascular risk				
Hypertension	752 (32)	463 (32)	284 (31)	0.56
Dyslipidemia	312 (13)	206 (14)	104 (11)	0.04
Diabetes mellitus	638 (27)	389 (27)	243 (27)	0.81
Cardiovascular disease	189 (8.0)	141 (9.8)	47 (5.1)	<0.001
Aspirin at admission	121 (5.1)	105 (7.3)	14 (1.5)	<0.001

Note: Data are given as n (%) or median (IQR). A total of 14 patients were not assigned to the aspirin or no aspirin group.

Abbreviations: BMI, body mass index; DCD, donation after circulatory death; HCC, hepatocellular carcinoma; IQR, interquartile range; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; RRT, renal replacement therapy; TACE, transarterial chemoembolization.

^aLife support is defined as hemodialysis and/or mechanical ventilation before transplantation.

U, one-way analysis of variance, and Kruskal–Wallis tests where appropriate. Differences among proportions derived from categorical data were compared using Fisher's exact or Pearson χ^2 tests where appropriate. Kaplan–Meier curves were used to estimate hepatic artery patency and rejection-free survival as well as patient and graft survival rates. Patients lost to follow-up or follow-up time ended were censored. Multivariable Cox regression analysis was performed to identify independent risk factors for cellular rejection. All *p* values were two-sided and considered statistically significant if *p* ≤ 0.05. Missing data are clearly reported in the article, and no extrapolation techniques were used to replace them. Statistical analysis was performed using R Studio Version 1.0.44 (RStudio, Inc., GNU Affero General Public License Version 3, Boston, MA) with the graphical user interface [rBiostatistics.com](https://www.biostatistics.com) beta version (GNU License, London, UK, 2017) and the Cloud Graphical User Interface for R Statistics and eLearning Platform (London, UK).

RESULTS

Study population

We report the effect of aspirin on ACR as well as the impact of aspirin on HAT. A total of 2366 LTs were performed in the 17 participating centers during the 3-year study period. The median follow-up time of the entire cohort was 62 months (IQR, 52–73 months); the 90-day mortality rate was 4.8%. The median recipient age of the primary LT cohort was 57 years (IQR, 49–62 years), and the majority of patients were male (*n* = 1587, 67%). At the time of LT, the median laboratory Model for End-Stage Liver Disease (MELD) score was 20 (IQR, 13–32), with 24% of patients having MELD scores >30. Only 15% of patients had life-support treatment before LT requiring ventilation support in 7% and/or renal replacement therapy (RRT) in 14% of cases. Most recipients (89%) received organs from DBD donors, and only 10% of organs were retrieved from DCD donors (Table 1). The piggyback technique

TABLE 2 Operative characteristics

	Total (n = 2365)	Aspirin (n = 1436)	No aspirin (n = 915)	p-value
Operation time, min	366 (300–456)	360 (295–457)	373 (300–454)	0.17
Cold ischemia time, min	420 (335–523)	420 (330–510)	430 (346–540)	<0.05
Veno-venous bypass	239 (10)	147 (10)	92 (10)	0.94
Simultaneous kidney transplantation	80 (3.4)	49 (3.4)	31 (3.4)	1.0
Intraoperative transfusion				
RBC, units	5 (2–10)	5 (2–10)	5 (3–10)	0.14
FFP, units	8 (4–18)	8 (4–17)	8 (4–18)	0.04
Platelets, units	3 (1–8)	3 (1–9)	4 (2–7)	0.57
Transplant technique				<0.001
Classic	1495 (63)	766 (53)	719 (79)	
Piggy back	870 (37)	670 (47)	196 (21)	
Arterial anatomy ^a				<0.001
Type 1	1779 (75)	1033 (72)	735 (80)	
Type 2	264 (11)	170 (12)	92 (10)	
Type 3	198 (8.4)	147 (10)	50 (5.5)	
Type 4	87 (3.7)	61 (4.2)	26 (2.8)	
Type 5	37 (1.6)	25 (1.2)	12 (1.3)	
Additional back-table reconstruction	299 (13)	213 (15)	84 (9.2)	<0.001
Biliary anastomosis				0.04
Duct-to-duct	2211 (93)	1337 (93)	860 (94)	
HJ	148 (6.3)	98 (6.8)	50 (5.5)	
None	6 (0.3)	1 (0.1)	5 (0.5)	

Note: Data are given as n (%) and median (IQR). 14 patients were not assigned to the Aspirin or no aspirin group.

Abbreviations: FFP, fresh frozen plasma; HJ, hepatico jejunostomy; LT, liver transplantation; RBC, red blood cells.

^aClassification refers to Hiatt et al.^[19]: Type 1, normal; Type 2, replaced (accessory) left hepatic artery from left gastric; Type 3, replaced (accessory) right hepatic artery from superior mesenteric; Type 4, double replaced system; Type 5, common hepatic artery from superior mesenteric.

was used in 37% of patients ($n = 870$), whereas 63% of recipients ($n = 1496$) underwent classical bicaval LT. Venovenous bypass during LT was used in 10% of patients ($n = 239$). Duct-to-duct anastomosis was the main biliary reconstruction technique (93%), whereas hepaticojejunostomy (HJ) was performed in 7% of patients. Further detailed characteristics of the LT population are presented in [Table 2](#).

Characteristics of the aspirin and no-aspirin groups

Prophylactic antiplatelet therapy with low-dose aspirin was administered in 1436 recipients (61%) after LT, whereas 915 recipients (39%) had no aspirin. Only two centers from the United Kingdom followed a strict policy of low-dose aspirin after LT. In all other participating centers, the decision to administer aspirin after LT was made on a rather pragmatic way, often driven by personal preference of the surgeon ([Figure 1](#)). In the aspirin group, the median postoperative day of

aspirin start was Day 2 (IQR, 1–9 days). Aspirin and no-aspirin groups were comparable in terms of sex, recipient age, and MELD score ([Table 1](#)). Most of the time, aspirin was administered lifelong and after 1 and 2 years 82% and 75% of patients were under low-dose aspirin.

In patients requiring dialysis prior to LT, aspirin was given in 53% of cases compared with 47% of patients without any dialysis prior to transplantation ($p < 0.05$). The same was found with patients on life support prior to LT (53% vs. 47%; $p < 0.001$). Patients who underwent transarterial chemoembolization (TACE) prior to LT were more likely to receive prophylactic low-dose aspirin after LT (67% vs. 33%; $p < 0.001$).

Characteristics and outcome of ACR

ACR was encountered in 17.7% of patients ($n = 420$) within the median follow-up time of 62 months (IQR, 52–73 months). Most of the rejections were biopsy proven (87%), whereas only 13% were classified as




FIGURE 1 Stacked bar plots of center-specific total case numbers and proportions of patients receiving low-dose aspirin (black) versus no aspirin (white) after LT. Center-specific aspirin use is displayed as percentage above each bar.

clinically suspicious without histology. The overall 1-, 3-, and 5-year rejection-free survival rates were 86%, 84%, and 83%, respectively, with 96% of the rejections occurring during the first year after LT. The 1-, 3-, and 5-year rejection-free survival rates for the aspirin versus no-aspirin groups were 89%, 87%, 84%, and 82%, 81%, 80%, respectively ($p < 0.05$) (Figure 2). Early ACR within 4 weeks after transplantation occurred in 6.8% (99/1436) in the aspirin versus 8.8% (81/915) in the no-aspirin group (odds ratio, 0.75; 95% confidence interval [CI], 0.55–1.03; $p = 0.08$). Immunosuppression between both groups was similar regarding maintenance immunosuppression with calcineurin inhibitors (CNIs), mycophenolate, and corticosteroids, but differed significantly in the use of monoclonal antibodies at the time of transplantation (aspirin 29% vs. no aspirin 15%) (Table 3). ACR was treated with steroids (37%), dose escalation of standard immunosuppressive regimen (14%), and other treatments including additional immunosuppressive medications (49%) (Table 4). Among patients with biopsy-proven ACR ($n = 362$), 182 (50%) were classified according to the Banff RAI by the local pathologist. Of the patients, 27% had intermediate rejection (RAI Grades 6–7), and 9.4% had severe rejection (RAI Grades 8–9).

On multivariate Cox regression analysis, aspirin was the strongest independent predictor for rejection-free survival with an HR of 0.77 (95% CI, 0.63–0.94; $p = 0.01$) followed by blood transfusions (Figure 2E). DCD organs showed the opposite effect, significantly triggering ACR with an HR of 1.37 (95% CI, 1.01–1.87; $p < 0.05$).

Hepatic artery patency rates

Overall hepatic arterial occlusion or stenosis occurred in 5.7% of patients ($n = 135$). Nearly all occlusions happened during the first year after LT (95%). The 1-year primary arterial patency rates were 99% in the aspirin

group and 96% in the no-aspirin group with an HR of 0.23 (95% CI, 0.13–0.40; $p < 0.001$) (Figure S2).

Patient and graft survival

The overall patient survival rate of primary LT after 1 year was 92% and 82% after 5 years. The 1-year graft survival rates in the aspirin group versus no-aspirin group were 93% and 88%, respectively, and 84% and 80% after 5 years, respectively (HR, 0.79; 95% CI, 0.65–0.96; $p < 0.05$) (Figure 2C). The overall graft survival rates after 1 and 5 years were 91% and 83%, respectively. The 1- and 5-year patient survival rates in the aspirin group versus no-aspirin group were 93% versus 89% and 83% versus 82%, respectively (Figure 2D).

DISCUSSION

The central finding that low-dose aspirin was associated with a lower risk of developing ACR is a somehow new and interesting aspect reflecting the anti-inflammatory properties of aspirin. Furthermore, the study findings support the concept of a prophylactic low-dose aspirin policy to prevent HAT. Because most of the rejection and arterial occlusion events occurred during the first 12 months after LT, this implies a low-dose aspirin policy at least for this early post-transplant period.

ACR is an acute T cell-mediated rejection that occurs frequently during the first year after LT. Data from a systematic review of randomized controlled trials showed that 15%–25% of recipients who took tacrolimus-based immunosuppression medications developed ACR.^[22] The most recent Scientific Registry of Transplant Recipients (SRTR) report from 2019 showed that 12.3% of all adult LT recipients develop at least one rejection episode during the first posttransplant year.^[23] Although the 1-year rate of ACR might be underreported, this figure mainly applies to a large




FIGURE 2 Kaplan–Meier curve plots of rejection-free survival for (A) the entire rejection cohort ($n = 420$) including biopsy-proven ($n = 364$) and clinically suspicious ACR ($n = 56$) and (B) only biopsy-proven ACR, (C) graft survival, and (D) overall survival for the aspirin and no-aspirin group. Survival groups were compared using the log-rank (Mantel–Cox) test. (E) Forrest plot is shown displaying adjusted HRs with the 95% CIs for significant and nonsignificant risk factors. Squares represent the HR, and the horizontal bars extend from the lower to the upper limit of the 95% CI of the HR estimate. Bold text indicates parameters of statistical or nearly statistical significance. [Color figure can be viewed at wileyonlinelibrary.com]

contemporary cohort with more than 80%–90% of patients on tacrolimus-based immunosuppression. These figures compare with the finding of the present study,

where the 1-year rate of biopsy-proven ACR was 17%, with 96% of rejection episodes occurring during the first posttransplant year.

TABLE 3 Post-transplant outcome

	Total (n = 2365)	Aspirin (n = 1436)	No aspirin (n = 915)	p-value
Peak transaminases				
AST, U/L	989 (452–1985)	946 (388–1873)	1091 (552–2167)	0.84
ALT, U/L	685 (346–1350)	703 (358–1423)	661 (331–1252)	0.12
Primary graft function				0.51
Normal allograft function	2114 (89)	1310 (91)	791 (86)	
Early allograft dysfunction ^a	229 (9.7)	114 (7.9)	114 (12.5)	
Primary non-function ^b	22 (0.1)	12 (8.1)	10 (6.2)	
Clavien-Classification ^c				<0.05
None or Minor (0-IIIa)	1496 (63)	945 (66)	542 (59)	
Major (IIIb-V)	869 (37)	491 (34)	373 (41)	
Bleeding complication ^d	353 (15)	182 (12.6)	171 (18.6)	<0.05
Hepatic arterial occlusion	59 (2.5)	15 (1.0)	44 (4.8)	<0.001
Hospitalization				
ICU stay, days	4 (2–8)	4 (2–8)	4 (2–8)	0.04
Hospital stay, days	16 (10–27)	15 (10–25)	18 (11–29)	<0.001
Readmission within 90 days	713 (30)	447 (31)	261 (29)	0.18
Immunosuppression				
Corticosteroids	2188 (92)	1331 (93)	848 (93)	1.0
Mycophenolate	1646 (70)	996 (71)	647 (69)	0.49
Tacrolimus	2139 (93)	1325 (92)	801 (88)	<0.05
Cyclosporine	293 (12)	159 (11)	134 (15)	0.01
Everolimus	105 (4.4)	84 (5.8)	20 (2.2)	<0.001
Monoclonal antibody	476 (20)	211 (29)	265 (15)	<0.001
Acute cellular rejection				
Total episodes	420 (18)	239 (17)	181 (20)	0.05
Rejection therapy				
Steroids	161 (73)	91 (70)	70 (81)	0.08
Dose escalation IS	72 (33)	44 (34)	28 (32)	0.88
Additional IS	53 (24)	35 (27)	18 (21)	0.34
Watchful waiting	24 (11)	7 (8.0)	17 (13)	0.28

Note: Data are given as n (%) and median (IQR). 14 patients were not assigned to the Aspirin or no aspirin group. Normal allograft function is defined as function not meeting the criteria of early allograft dysfunction and primary non-function.

Abbreviations: ALT, alanin aminotransferase; AST, aspartat aminotransferase; ICU, intensive care unit; LT, liver transplantation.

^aRefers to Olthoff et al.^[20]

^bRefers to Hartog et al.^[21]

^cRefers to Dindo et al.^[15]

^dOverall, including all Clavien-Dindo-Complications.

In the present study, most rejections were based on histological evaluation, which is still the gold standard to diagnose and grade ACR.^[24,25] Liver biopsies for allograft rejection are usually performed in the clinical scenario of abnormal liver function tests in the absence of vascular or biliary complications.^[26] In our study, only 13% of all rejections were not biopsy proven and were categorized as clinical suspicious rejection. Some clinicians have treated such rejections empirically and reserve liver biopsies for unresponsive treatment.^[26]

The histological diagnosis of ACR is based on the three categories of portal, bile duct, and venous

endothelial inflammation and is usually graded using the Banff RAI.^[16] Aspirin, which is frequently used either after LT to prevent HAT or for medical vascular conditions, has anti-inflammatory properties^[8] and might mitigate rejection-associated inflammation. This assumption triggered our hypothesis that aspirin might confer anti-inflammatory protection against ACR. We have shown that the use low-dose aspirin after LT decreased the rate of ACR and was associated with superior rejection-free survival, especially during the first posttransplant year along with a small but significant protective effect against HAT. To exclude any

TABLE 4 Characteristics of biopsy proven and clinically suspected rejections

	No rejection (N = 1945)	Biopsy-proven rejection (N = 364)	Clinically suspected rejection (N = 56)	p
Age, years	57 (49–62)	55 (47–61)	60 (50–66)	<0.001
Male sex	1312 (68)	236 (65)	39 (70)	0.57
MELD	20 (13–29)	20 (13–31)	19 (14–22)	0.68
DCD	192 (10)	42 (12)	7 (13)	0.53
Cold ischemia time, hours	7 (6–9)	7 (5–8)	8 (6–9)	<0.001
Aspirin at discharge	1197 (62)	210 (57)	50 (80)	0.07
RBC	1457 (77)	257 (72)	40 (80)	0.07
HCC	706 (36)	133 (37)	19 (34)	0.93
Immunosuppression				
CNI-Inhibitor maintenance	1777 (91)	314 (86)	48 (86)	<0.05
Monoclonal antibodies	394 (20)	68 (19)	14 (25)	0.52
Rejection treatment				<0.001
Corticosteroids	–	133 (37)	27 (48)	
Dose escalation	–	52 (14)	19 (34)	
Others	–	179 (49)	10 (18)	

Note: Data are given as n (%) and median (IQR).

Abbreviations: CNI, calcineurin inhibitor; DCD, donation after cardiac death; HCC, hepatocellular carcinoma; MELD, Model for End Stage Liver Disease; RBC, red blood cells.

confounding effect of immunosuppression with the use of aspirin, we included both the use of CNI and induction therapy with monoclonal antibodies in our Cox regression analysis and independently identified aspirin as a protective factor against ACR. This central and novel finding implies that the prophylactic application of low-dose aspirin after LT can be used as dual protection against ACR as well as HAT, especially during the vulnerable period of the first posttransplant year.

The observation that the nonaspirin group was sicker might imply that adverse outcomes were more likely to occur compared with the aspirin group. This finding might assume that the beneficial effects of aspirin were rather related to the higher acuity of the recipient than the anti-inflammatory and antithrombotic properties of aspirin. To address this potential confounding effect, we included parameters of medical acuity such as pre-transplant life support (dialysis and/or ventilation) and MELD scores <30 in our multivariate analysis.

Our multivariate analysis also identified two other important risk factors for ACR that we would like to highlight. First, perioperative red blood cell (RBC) transfusions improved rejection-free survival after primary LT. This effect, also known as transfusion-related immunomodulation (TRIM), has been initially reported in the renal transplant setting, when significantly improved renal allograft survival was observed in transplant recipients who received RBC transfusions.^[27] Although the immunosuppressive mechanisms of TRIM are not yet fully elucidated, impaired natural killer cell function and macrophage phagocytosis, defective antigen presentation, and suppression of lymphocytic proliferation are described as immunosuppressive

alterations.^[28–32] These immunosuppressive effects of RBC TRIM might play an important role in why the factor RBC transfusion was an almost independent protective factor against ACR in our multivariate analysis. Second, our multivariate analysis identified allografts from DCD as an independent risk factor for ACR. However, this finding appears divergent from many studies reporting similar rejection rates for DBD and DCD organs.^[33–35]

Aspirin was also associated with significantly superior graft and overall survival rates in the present study, although the magnitude of this benefit was smaller compared with rejection-free survival. Although past studies suggested no association between ACR and graft survival,^[36–38] a recent study analyzing the Adult-to-Adult Living Donor Liver Transplantation Cohort Study and SRTR cohort found that ACR was associated with an increased risk of developing graft failure and graft failure–related death.^[39] How much the effect of aspirin on ACR exactly contributed to the superior graft and patient survival is unclear, but other beneficial effects on arterial patency and medical conditions might have contributed as well.

The strength of this study relates to the large multi-center study design with a well-defined contemporary study population of more than 2300 primary LT recipients. The contemporary nature of the study population is not only reflected by the recent 3-year study period but also by the fact that more than 90% of the recipients were on tacrolimus-based immunosuppression. In addition, the median follow-up time of more than 5 years provided a long observational basis for the primary outcome measures. The study was also associated with

certain limitations that relate to the heterogeneity of posttransplant management among centers, including aspirin use, immunosuppression, and liver-biopsy decision making. In addition, the lack of biopsy-proven diagnosis in the scenario of clinically suspicious rejection might misallocate those patients to the rejection versus nonrejection group.

In conclusion, low-dose aspirin protects against both rejection and HAT, which translates to improved graft and patient survival rates. The findings of this contemporary cohort study should encourage evaluating low-dose aspirin use after primary LT to protect the liver graft from ACR and maintain arterial patency.

ACKNOWLEDGMENT

The authors thank Patricia Martinez, user-experience designer (ch.linkedin.com/in/pmartinezch/en), for the map she created. Open access funding provided by Universitat Zurich.

CONFLICT OF INTEREST

Parissa Tabrizian received honoraria from Bayer AG. Varvara Kirchner consults for Natera.

ORCID

Christian E. Oberkofler  <https://orcid.org/0000-0002-7330-3876>

Takahiro Ito  <https://orcid.org/0000-0002-1876-3052>

Alessandro Parente  <https://orcid.org/0000-0001-5506-224X>

Paolo Magistri  <https://orcid.org/0000-0001-8326-069X>

Pierre-Alain Clavien  <https://orcid.org/0000-0002-9916-7905>

Ronald W. Busuttil  <https://orcid.org/0000-0001-8157-1531>

Henrik Petrowsky  <https://orcid.org/0000-0001-5744-0531>

REFERENCES

- Ekser B, Halazun KJ, Petrowsky H, Balci D. Liver transplantation and hepatobiliary surgery in 2020. *Int J Surg*. 2020;82S:1–3.
- Piardi T, Lhuaiere M, Bruno O, Memeo R, Pessaux P, Kianmanesh R, et al. Vascular complications following liver transplantation: a literature review of advances in 2015. *World J Hepatol*. 2016;8:36–57.
- Oberkofler CE, Raptis DA, DiNorcia J, Kaldas FM, Müller PC, Pita A, et al. How to handle arterial conduits in liver transplantation? Evidence from the first multicenter risk analysis. *Ann Surg*. 2020;274:1032–42.
- Muller X, Marcon F, Sapisochin G, Marquez M, Dondero F, Rayar M, et al. Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. *Ann Surg*. 2018;267:419–25.
- Mourad MM, Liossis C, Gunson BK, Mergental H, Isaac J, Muiesan P, et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation. *Liver Transpl*. 2014;20:713–23.
- Vivarelli M, La Barba G, Cucchetti A, Lauro A, del Gaudio M, Ravaioli M, et al. Can antiplatelet prophylaxis reduce the

incidence of hepatic artery thrombosis after liver transplantation? *Liver Transpl*. 2007;13:651–4.

- Shay R, Taber D, Pilch N, Meadows H, Tischer S, McGillicuddy J, et al. Early aspirin therapy may reduce hepatic artery thrombosis in liver transplantation. *Transplant Proc*. 2013;45:330–4.
- Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. *J Immunol*. 2009;183:2089–96.
- Patrono C, Ciabattini G, Pinca E, Pugliese F, Castrucci G, de Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. *Thromb Res*. 1980;17:317–27.
- Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. *Science*. 1994;265:956–9.
- Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. *Science*. 1996;274:1383–5.
- Kim M, Bergmark BA, Zelniker TA, Mehra MR, Stewart GC, Page DS, et al. Early aspirin use and the development of cardiac allograft vasculopathy. *J Heart Lung Transplant*. 2017;36:1344–9.
- Grotz W, Siebig S, Olschewski M, Strey CW, Peter K. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. *Transplantation*. 2004;77:1848–53.
- Raptis DA, Mettler T, Fischer MA, Patak M, Lesurtel M, Eshmunov D, et al. Managing multicentre clinical trials with open source. *Inform Health Soc Care*. 2014;39:67–80.
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–13.
- Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. *Hepatology*. 2000;31:792–9.
- Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. Acute and chronic rejection after liver transplantation: what a clinician needs to know. *J Clin Exp Hepatol*. 2017;7:358–66.
- Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. *J Vasc Surg*. 2002;35:603–10.
- Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. *Ann Surg*. 1994;220:50–2.
- Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transpl*. 2010;16:943–9.
- Hartog H, Hann A, Perera MTPR. Primary nonfunction of the liver allograft. *Transplantation*. 2022;106:117–28.
- Rodríguez-Perálvarez M, Rico-Juri JM, Tsochatzis E, Burra P, de la Mata M, Lerut J. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. *Transpl Int*. 2016;29:961–73.
- Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2019 annual data report: liver. *Am J Transplant*. 2021;21(Suppl 2):208–315.
- Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. *Transpl Int*. 2010;23:971–83.
- Krenzien F, Keshi E, Splith K, Griesel S, Kamali K, Sauer IM, et al. Diagnostic biomarkers to diagnose acute allograft rejection after liver transplantation: systematic review and meta-analysis of diagnostic accuracy studies. *Front Immunol*. 2019;10:758.
- Rodríguez-Perálvarez M, García-Caparrós C, Tsochatzis E, Germani G, Hogan B, Poyato-González A, et al. Lack of

- agreement for defining 'clinical suspicion of rejection' in liver transplantation: a model to select candidates for liver biopsy. *Transpl Int*. 2015;28:455–64.
27. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. *N Engl J Med*. 1978;299:799–803.
 28. Ghio M, Contini P, Negrini S, Mazzei C, Zocchi MR, Poggi A. Down regulation of human natural killer cell-mediated cytotoxicity induced by blood transfusion: role of transforming growth factor-beta(1), soluble Fas ligand, and soluble class I human leukocyte antigen. *Transfusion*. 2011;51:1567–73.
 29. Long K, Meier C, Bernard A, Williams D, Davenport D, Woodward J. T-cell suppression by red blood cells is dependent on intact cells and is a consequence of blood bank processing. *Transfusion*. 2014;54:1340–7.
 30. Long K, Meier C, Ward M, Williams D, Woodward J, Bernard A. Immunologic profiles of red blood cells using in vitro models of transfusion. *J Surg Res*. 2013;184:567–71.
 31. Muszynski J, Nateri J, Nicol K, Greathouse K, Hanson L, Hall M. Immunosuppressive effects of red blood cells on monocytes are related to both storage time and storage solution. *Transfusion*. 2012;52:794–802.
 32. Ottonello L, Ghio M, Contini P, Bertolotto M, Bianchi G, Montecucco F, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. *Transfusion*. 2007;47:1395–404.
 33. Hann A, Osei-Bordom DC, Neil DAH, Ronca V, Warner S, Perera MTPR. The human immune response to cadaveric and living donor liver allografts. *Front Immunol*. 2020;11:1227.
 34. Bellingham JM, Santhanakrishnan C, Neidlinger N, Wai P, Kim J, Niederhaus S, et al. Donation after cardiac death: a 29-year experience. *Surgery*. 2011;150:692–702.
 35. Wells M, Croome KM, Janik T, Hernandez-Alejandro R, Chandok N. Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis. *Can J Gastroenterol Hepatol*. 2014;28:103–8.
 36. Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. *Liver Transpl Surg*. 1995;1:10–5.
 37. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases liver transplantation database. *Liver Transpl Surg*. 1999;5(Suppl 1):S107–14.
 38. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. *Hepatology*. 1998;28:638–45.
 39. Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. *Clin Gastroenterol Hepatol*. 2017;15:584–93.e2.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Oberkofler CE, Raptis DA, Müller PC, Sousa da Silva RX, Lehmann K, Ito T. Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation. *Liver Transpl*. 2022;28:1888–1898. <https://doi.org/10.1002/lt.26534>